

Company


TWOCELLS COMPANY, Limited


Presenter

**Masahiro
Nagaya**

Who we are; conducting a *phase III clinical trial* for “gMSC[®]1”

- A venture business established in 2003, spun out from Hiroshima Univ.
- Successfully developed the serum-free media for MSC culture, “STK[®]” series
- STK[®] series enable to get sufficient MSC in number, with higher qualities and enhanced safety (without serum-related risks)
- Utilizing the STK[®] series, **developed the “gMSC[®]1,” a regenerative cellular medicine** for chondrogenesis in the knee with the support of Chugai Pharmaceuticals Co., Ltd.

STK[®] series

Trial for gMSC[®]1

- Phase III trial
- Open-labeled RCT
- Mfx as control



Upcoming Product Pipelines (candidates)

gMSC[®]2:

- for brain stroke
- In collaboration with Otsuka Pharmaceuticals Co., Ltd.

gMSC[®]3:

- for damaged cartilage
- with lesser invasiveness (e.g. Inj.)
- In collaboration with Meiji Seika Pharma Co., Ltd.

gMSC[®]4:

- for chronic kidney disease
- prevention in severity

And other possibilities
at the **Booth V-79**

